Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24017140 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL29897740 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL3250967 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL3257546 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL21645338 | 0.85 | ALDH1A1 (0.48) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL148751 | 0.81 | ADRB2 (0.54) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL382596 | 0.81 | ADRB2 (0.54) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL30504213 | 0.81 | ADRB2 (0.54) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL25310844 | 0.81 | ALDH1A1 (0.44) | ALDH1A1PNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL13666761 | 0.81 | ADRB2 (0.54) | ALDH1A1PNMTOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117255715-A | Catalytic material suitable for hydrogenation reactions comprising Ni, one or more additional metals M and a specific oxidation support material | 巴斯夫欧洲公司 | 2023-12-19 | — | — | CN | disclosed |
| US-10364258-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190055269-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055269-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885F2 3419/4885PNMT 2349/4885 |
| US-10364258-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885F2 3419/4885PNMT 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.